Navigation Links
Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
Date:1/7/2009

THOUSAND OAKS, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will present at the 27th Annual JP Morgan Global Healthcare Conference at 9:00 a.m. Pacific Time on Monday, Jan. 12, 2009, at the Westin St. Francis in San Francisco, Calif. Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)

Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    CONTACT: Amgen, Thousand Oaks
    David Polk, 805-447-4613 or 805-490-0661 (media)
    Arvind Sood, 805-447-1060 (investors)


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... January 22, 2015 Diagenode, Inc., ... as the Bioruptor® and complete solutions for epigenetics ... chromatin immunoprecipitation, alleviating the need for manual processing. ... needed for ChIP of histones or transcription factors ...
(Date:1/22/2015)... ALTO, Calif. , Jan. 22. 2015  Varian Medical Systems ... and software, has been honored for its commitment to sustainability ... sustainable companies. Varian is the highest ranked healthcare equipment company ... announced today during the World Economic Forum at ...
(Date:12/25/2014)... The report “Service Quality Management and ... Provider Type - Global Advancements, Worldwide Forecasts & Analysis ... analysis and forecasting of revenues. , Browse 152 ... and in-depth TOC on “Service Quality Management (SQM) and ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... Mass., May 2, 2011 Richard Resnick, GenomeQuest,s ... on Tuesday, May 3, 2011, at the Biomarker ... Next Generation/Whole-Genome Sequencing on Companion Diagnostics" for pharmaceutical ... generation sequencing and data management technologies. ...
... 2011 Dyadic International, Inc. ("Dyadic") (OTC Pink: ... discovery, development, manufacture and sale of enzyme and ... enzyme industries, announced today that its research and ... entered into a research agreement with Sanofi Pasteur, ...
... 2, 2011 Saladax Biomedical, Inc., a privately held ... the promise of personalized medicine for new and existing ... team to expand its European presence. Reporting ... members of Saladax,s European commercialization team include: ...
Cached Biology Technology:GenomeQuest to Lead Biomarker World Congress Panel on Applying Whole Genome Sequencing to Developing Companion Diagnostics 2Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio 2Saladax Biomedical, Inc. Announces European Commercialization Team 2Saladax Biomedical, Inc. Announces European Commercialization Team 3
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... Jan. 22, 2015   EyeLock, Inc. , a market leader ... Steve Gerber to the new role of Senior ... for leading development of mobile platforms and wearable solutions for ... and innovation in the semiconductor industry to his role at ...
(Date:12/22/2014)... Conn. , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce market, ... Apollo Robbins for the 2015 International CES debut ... Apollo Robbins will be at the NXT-ID booth January ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... may be just what the doctor orders for individuals suffering ... production or altered tear film composition. According to a study ... temperature less than 30 degrees Celsius on the eye and ... of the disorder. The study, (Meibomian Lipid Films and ...
... from the Swedish medical university Karolinska Institutet has deepened ... most fundamental processes, works. In a long term perspective ... The study is presented in the prestigious scientific journal ... yeast cells, researchers at Karolinska Institutet have discovered that ...
... Thursday, May 26, the University of Delaware will ... honor of Richard F. Heck, Willis F. Harrington ... of the 2010 Nobel Prize in Chemistry. Register ... Akira Suzuki of Japan,s Hokkaido University, and Ei-Ichi ...
Cached Biology News:Drop in temperature may explain the increase in dry eye suffering 2Research into chromosome replication reveals details of heredity dynamics 2Symposium honoring UD Nobel Laureate Richard Heck set for May 26 2
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Goat polyclonal to HA1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: TLGSCRERQPEFV from the C terminus of human HA1. Entrez GeneID: 23526 Swiss Protein ID: O78181...
Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
Biology Products: